Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
17 evidence topics · 19 sources
U.S. breast cancer deaths, 2026
Contribution of metastatic disease treatment to the decline in U.S. mortality
U.S. 5-year relative survival for HR-positive/HER2-negative disease by stage, SEER 21, 2016 to 2022
Goals of treatment for metastatic disease
U.S. survival after de novo metastatic diagnosis over time
“Median relative survival time increased from 22.3 to 38.7 months and from 19.1 to 29.7 months for women diagnosed between ages 15–49 and 50–64, respectively, during 1992–1994 versus 2005–2012.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite a poor prognosis there is a small but meaningful percent of these cases who survive 10-years or more; more than 11% of women diagnosed between 2000–2004 under the age of 64 years survived 10 years or more.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. breast cancer-specific survival in de novo HR-positive/HER2-negative metastatic disease before and after CDK4/6 inhibitors
“In the unadjusted analysis of patients with HR+/HER2− mBC, BCSS was significantly longer among patients in the post-2015 group versus the pre-2015 group (median BCSS: 39 [95% CI 38–42] vs 35 [95% CI 33–37] months; hazard ratio [HR] = 0.896, 95% CI 0.849–0.946; p < 0.001;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 48-month BCSS rate was 44.5% for the post-2015 group and 38.5% for the pre-2015 group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. real-world overall survival with first-line CDK4/6 inhibitor plus aromatase inhibitor
“Of 9146 eligible patients, 6831, 1279, and 1036 received palbociclib plus AI, ribociclib plus AI, or abemaciclib plus AI, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After sIPTW, median OS was 54.6 months (95% CI 52.6-56.4 months) in the palbociclib group, 59.0 months (95% CI 50.9-66.1 months) in the ribociclib group, and 64.5 months (95% CI 55.4 months-not estimable) in the abemaciclib group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. real-world outcomes of second-line therapy after progression on a first-line CDK4/6 inhibitor
“A total of 839 patients received a documented second-line therapy after progression on first-line CDK4/6i treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median unadjusted rwPFS and OS for those who received a CDK4/6i in the second-line setting were 8.25 months and 35.7 months, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review: real-world progression-free survival after a first-line CDK4/6 inhibitor
“Twenty records (9 full-text articles and 11 conference abstracts) encompassing 18 unique studies met the eligibility criteria and reported outcomes for second-line (2 L) treatments after 1 L CDK4/6i; no studies reported disaggregated outcomes in the third-line setting or beyond.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second- and third-line real-world progression-free survival by intrinsic subtype, Spain
“Median rwPFS-2L was 7.2 months in luminal IS vs. 6.1 in non-luminal (HR 1.40; 95% CI 0.86–2.30); the Basal-like (BL) subtype correlated with significantly shorter rwPFS-2L (HR 3.82; 95% CI 1.07–13.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acquired ESR1 mutations along the treatment course
“Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, ESR1 mutations usually occur with several concurrent genomic alterations, and together, these confer a globally worse prognosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 mutation and overall survival after prior aromatase inhibitor, BOLERO-2
“Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These mutations were associated with shorter overall survival (wild-type, 32.1 months [95% CI, 28.09-36.40 months]; D538G, 25.99 months [95% CI, 19.19-32.36 months]; Y537S, 19.98 months [13.01-29.31 months]; both mutations, 15.15 months [95% CI, 10.87-27.43 months]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide population-level survival trends in de novo and recurrent metastatic disease
“For dnMBC, 13 of 14 studies reported improved OS or BCSS since 1995. In 2005–2009, the median OS was 26 months (range 24–30), a median gain of 6 months since 1995–1999 (range 0–9, 4 studies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For rMBC, one study reported no change in survival between 1998 and 2006 and 2007–2013 (median OS 23 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Population-level improvements in OS for dnMBC have not been consistently observed in rMBC cohorts nor older women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide mortality, GLOBOCAN 2024
“Among women, breast cancer is the most common cancer for both incidence and mortality worldwide, ranking first for incidence in 164 countries” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality rates range from 20 to 25 per 100,000 in Melanesia, Micronesia/Polynesia, and Western Africa and from six to 10 per 100,000 in Eastern Asia and Central America.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide survival gains in ER-positive/HER2-negative advanced disease
“While important progress has been made, including the doubling of the median overall survival for two of the three ABC subtypes, the disease remains incurable for the vast majority of patients and inequities in access to the best diagnostic and therapeutic options and to high quality, multidisciplinary, evidence-based care have increased in the last decade.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote